HIV vaccine trial in Africa halted after disappointing initial results
The first PrEPVacc volunteer participant receives an injection at the launch of the launch of the PrePVacc Trial at the Masaka site of the MRC/UVRI and LSHTM Uganda Research Unit, on December 15, 2020. PHOTO | PrEPVacc Investigators
Josephine Christopher is a senior business journalist for The Citizen and Mwananchi newspapers
Mwananchi Communications Limitted
What you need to know:
The trial's findings, however, underscore the ongoing challenges in developing an effective HIV vaccine and the need for continued research and exploration of alternative prevention strategies.
